The therapy with octreotide in subjects with acromegaly improves the glucose profile if normal glycaemia is found at baseline according to GH and IGF1 lowering and, if the patients already have diabetes mellitus, only partial glucose control is found, as GH and IGF1 are inadequately suppressed. The gene discussed is GH1; the disease is acromegaly.